Histoplasmosis in HIV-Infected Patients: A Review of New Developments and Remaining Gaps

Current Tropical Medicine Reports

Volumn 1, Issue 2, 2014, Pages 119-128

  Adenis, Antoine A ^a,b   Aznar, Christine ^b,c   Couppié, Pierre ^b,d  

^a INSERM   (France)

^b UNIVERSITÉ DES ANTILLES ET DE LA GUYANE   (France)

^c Lab Hosp Univ de Parasitologie   (France)

^d Centre Hospitalier de Cayenne   (France)

Author keywords

AIDS; Fungal disease; Histoplasma; Histoplasmosis; HIV; Tropical medicine; Tropical mycosis

Indexed keywords

ALKALINE PHOSPHATASE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; FERRITIN; ITRACONAZOLE; LACTATE DEHYDROGENASE; POSACONAZOLE; VORICONAZOLE;

AJELLOMYCES CAPSULATUS; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SUBSTITUTION; ENZYME IMMUNOASSAY; GEOGRAPHIC DISTRIBUTION; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KIDNEY FAILURE; LOOP MEDIATED ISOTHERMAL AMPLIFICATION; MOLECULAR EPIDEMIOLOGY; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOM AMPLIFIED POLYMORPHIC DNA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS;

EID: 84919949612     PISSN: None     EISSN: 21963045     Source Type: Journal    
DOI: 10.1007/s40475-014-0017-8     Document Type: Review

References (87)

1. Darling ST. A protozoon general infection producing pseudotubercles in the lungs and focal necrosis in the liver, spleen and lymphnodes. JAMA. 1906;46:1283–5.
2. Wheat LJ, Connolly-Stringfield PA, Baker RL, Curfman MF, Eads ME, Israel KS, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore). 1990;69(6):361–74.
3. Gutierrez ME, Canton A, Sosa N, Puga E, Talavera L. Disseminated histoplasmosis in patients with AIDS in Panama: a review of 104 cases. Clin Infect Dis. 2005;40(8):1199–202.
4. Huber F, Nacher M, Aznar C, Pierre-Demar M, El Guedj M, Vaz T, et al. AIDS-related Histoplasma capsulatum var. capsulatum infection: 25 years experience of French Guiana. AIDS. 2008;22(9):1047–53.
5. Arango M, Castaneda E, Agudelo CI, De Bedout C, Agudelo CA, Tobon A, et al. Histoplasmosis: results of the Colombian national survey, 1992-2008. Biomedica. 2011;31(3):344–56.
6. Pontes LB, Leitao Tdo M, Lima GG, Gerhard ES, Fernandes TA. Clinical and evolutionary characteristics of 134 patients with disseminated histoplasmosis associated with AIDS in the State of Ceara. Rev Soc Bras Med Trop. 2010;43(1):27–31.
7. Pan B, Chen M, Pan W, Liao W. Histoplasmosis: a new endemic fungal infection in China? Review and analysis of cases. Mycoses. 2013;56(3):212–21.
8. Peigne V, Dromer F, Elie C, Lidove O, Lortholary O. Imported acquired immunodeficiency syndrome-related histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy eras. Am J Trop Med Hyg. 2011;85(5):934–41.
9. Antinori S, Magni C, Nebuloni M, Parravicini C, Corbellino M, Sollima S, et al. Histoplasmosis among human immunodeficiency virus-infected people in Europe: report of 4 cases and review of the literature. Medicine (Baltimore). 2006;85(1):22–36.
10. Ashbee HR, Evans EG, Viviani MA, Dupont B, Chryssanthou E, Surmont I, et al. Histoplasmosis in Europe: report on an epidemiological survey from the European Confederation of Medical Mycology Working Group. Med Mycol. 2008;46(1):57–65.
11. Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. 2007;20(1):115–32.
12. Jones PG, Cohen RL, Batts DH, Silva Jr J. Disseminated histoplasmosis, invasive pulmonary aspergillosis, and other opportunistic infections in a homosexual patient with acquired immune deficiency syndrome. Sex Transm Dis. 1983;10(4):202–4.
13. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep. 1987;36 Suppl 1:1S-15S.
14. Homei A, Worboys M. Fungal Disease in Britain and the United States 1850-2000 Mycoses and Modernity. 2013/11/15 ed. Centre for the History of Science TaM, University of Manchester, England (http://chstm.manchester.ac.uk), editor. Manchester, England: Palgrave Macmillan; 2013.
15. Nacher M, Adenis A, Aznar C, Blanchet D, Vantilcke V, Demar M, et al. How Many Have Died from Undiagnosed Human Immunodeficiency Virus-Associated Histoplasmosis, A Treatable Disease? Time to Act. Am J Trop Med Hyg. 2013.
16. Myint T, Al-Hasan MN, Ribes JA, Murphy BS, Greenberg RN. Temporal Trends, Clinical Characteristics, and Outcomes of Histoplasmosis in a Tertiary Care Center in Kentucky, 2000 to 2009. J Int Assoc Provid AIDS Care. 2013
17. Nacher M, Adenis A, Mc Donald S. Do Socorro Mendonca Gomes M, Singh S, Lopes Lima I, et al. Disseminated Histoplasmosis in HIV-Infected Patients in South America: A Neglected Killer Continues on Its Rampage. PLoS Negl Trop Dis. 2013;7(11):e2319.
18. Brandt ME, Gómez BL, Warnock D. Histoplasma, Blastomyces, Coccidioides, and other dimorphic fungi causing systemic mycoses In: D VJaW, editor. Manual of Clinical Microbiology, 10th edition. Washington DC; 2011. p. 1902-18.
19. Edwards JA, Rappleye CA. Histoplasma mechanisms of pathogenesis–one portfolio doesn't fit all. FEMS Microbiol Lett. 2011;324(1):1–9.
20. Kasuga T, White TJ, Koenig G, McEwen J, Restrepo A, Castaneda E, et al. Phylogeography of the fungal pathogen Histoplasma capsulatum. Mol Ecol. 2003;12(12):3383–401.
21. Loulergue P, Bastides F, Baudouin V, Chandenier J, Mariani-Kurkdjian P, Dupont B, et al. Literature review and case histories of Histoplasma capsulatum var. duboisii infections in HIV-infected patients. Emerg Infect Dis. 2007;13(11):1647–52.
22. Karimi K, Wheat LJ, Connolly P, Cloud G, Hajjeh R, Wheat E, et al. Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil. J Infect Dis. 2002;186(11):1655–60.
23. Goldani LZ, Aquino VR, Lunardi LW, Cunha VS, Santos RP. Two specific strains of Histoplasma capsulatum causing mucocutaneous manifestations of histoplasmosis: preliminary analysis of a frequent manifestation of histoplasmosis in southern Brazil. Mycopathologia. 2009;167(4):181–6.
24. Couppie P, Aznar C, Carme B, Nacher M. American histoplasmosis in developing countries with a special focus on patients with HIV: diagnosis, treatment, and prognosis. Curr Opin Infect Dis. 2006;19(5):443–9.
25. Smith JA, Jt R, Kauffman CA. Cutaneous manifestations of endemic mycoses. Curr Infect Dis Rep. 2013;15(5):440–9.
26. Muniz Mde M, Morais ESTP, Meyer W, Nosanchuk JD, Zancope-Oliveira RM. Comparison of different DNA-based methods for molecular typing of Histoplasma capsulatum. Appl Environ Microbiol. 2010;76(13):4438–47.
27. Wheat LJ. Histoplasmosis: a review for clinicians from non-endemic areas. Mycoses. 2006;49(4):274–82.
28. Colombo AL, Tobon A, Restrepo A, Queiroz-Telles F, Nucci M. Epidemiology of endemic systemic fungal infections in Latin America. Med Mycol. 2011;49(8):785–98.
29. Ajello L. The medical mycological iceberg. HSMHA Health Rep. 1971;86(5):437–48.
30. Skillman D, Davis B, Harris JR, Nett RJ. Histoplasmosis in a state where it is not known to be endemic–Montana, 2012–2013. MMWR Morb Mortal Wkly Rep. 2013;62(42):834–7.
31. Allard A, Décarie D, Grenier JL, Lacombe MC, Levac F. Histoplasmosis outbreak associated with the renovation of an old house - Quebec, Canada, 2013. MMWR Morb Mortal Wkly Rep. 2014;62(51–52):1041–4.
32. Cruz R. Histoplasma capsulatum var. capsulatum Darling. Rev Chilena Infectol. 2013;30(3):311–2.
33. Garsaud P, Boisseau-Garsaud AM, Desbois N, Verneuil L, Cales-Quist D, Helenon R, et al. Epidemiology of histoplasmosis in the French West Indies (Martinique). Trans R Soc Trop Med Hyg. 1999;93(3):264–7.
34. Fernandez Andreu CM, Martinez Machin G. The sources of histoplasmosis infection on the Isla de la Juventud, Cuba. Rev Inst Med Trop Sao Paulo. 1992;34(5):441–6.
35. Gopalakrishnan R, Nambi PS, Ramasubramanian V, Abdul Ghafur K, Parameswaran A. Histoplasmosis in India: truly uncommon or uncommonly recognised? J Assoc Physicians India. 2012;60:25–8.
36. Bulmer AC, Bulmer GS. Incidence of histoplasmin hypersensitivity in the Philippines. Mycopathologia. 2001;149(2):69–71.
37. Chakrabarti A, Slavin MA. Endemic fungal infections in the Asia-Pacific region. Med Mycol. 2011;49(4):337–44.
38. McLeod DS, Mortimer RH, Perry-Keene DA, Allworth A, Woods ML, Perry-Keene J, et al. Histoplasmosis in Australia: report of 16 cases and literature review. Medicine (Baltimore). 2011;90(1):61–8.
39. Wheat J. Endemic mycoses in AIDS: a clinical review. Clin Microbiol Rev. 1995;8(1):146–59.
40. Hajjeh RA, Pappas PG, Henderson H, Lancaster D, Bamberger DM, Skahan KJ, et al. Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons. Clin Infect Dis. 2001;32(8):1215–20.
41. Nacher M, Adenis A, Adriouch L, Dufour J, Papot E, Hanf M, et al. What is AIDS in the Amazon and the Guianas? Establishing the burden of disseminated histoplasmosis. Am J Trop Med Hyg. 2011;84(2):239–40.
42. Baddley JW, Sankara IR, Rodriquez JM, Pappas PG, Many Jr WJ. Histoplasmosis in HIV-infected patients in a southern regional medical center: poor prognosis in the era of highly active antiretroviral therapy. Diagn Microbiol Infect Dis. 2008;62(2):151–6.
43. Moquet O, Blanchet D, Simon S, Veron V, Michel M, Aznar C. Histoplasma capsulatum in Cayenne. Mycopathologia: French Guiana; 2012.
44. Hanf M, Adenis A, Couppie P, Carme B, Nacher M. HIV-associated histoplasmosis in French Guiana: recent infection or reactivation? AIDS. 2010;24(11):1777–8.
45. Kroetz DN, Deepe GS. The role of cytokines and chemokines in Histoplasma capsulatum infection. Cytokine. 2012;58(1):112–7.
46. Hanf M, Adenis A, Carme B, Couppie P, Nacher M. Disseminated Histoplasmosis Seasonal Incidence Variations: A Supplementary Argument for Recent Infection? J AIDS Clin Res. 2012;2012:3(8).
47. McKinsey DS, Spiegel RA, Hutwagner L, Stanford J, Driks MR, Brewer J, et al. Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: incidence, risk factors, and pathophysiology. Clin Infect Dis. 1997;24(6):1195–203.
48. Segura L, Rojas M, Pelaez N, Shor-Posner G, RosaRe D, Moreno J, et al. Disseminated histoplasmosis and human immunodeficiency virus type 1 infection: risk factors in Guatemala. Clin Infect Dis. 1997;25(2):343–4.
49. Nacher M, Adenis A, Blanchet D, Vantilcke V, Demar M, Basurko C, et al. Risk Factors for Disseminated Histoplasmosis in a Cohort of HIV-Infected Patients in French Guiana. PLoS Negl Trop Dis. 2014;8(1):e2638.
50. Singh N, Huprikar S, Burdette SD, Morris MI, Blair JE, Wheat LJ. Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, infectious diseases community of practice. Am J Transplant. 2012;12(9):2414–28.
51. Wheat LJ, Chetchotisakd P, Williams B, Connolly P, Shutt K, Hajjeh R. Factors associated with severe manifestations of histoplasmosis in AIDS. Clin Infect Dis. 2000;30(6):877–81.
52. Breton G, Adle-Biassette H, Therby A, Ramanoelina J, Choudat L, Bissuel F, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS. 2006;20(1):119–21.
53. Adenis A, Nacher M, Hanf M, Basurko C, Dufour J, Huber F, et al. Tuberculosis and Histoplasmosis among Human Immunodeficiency Virus-Infected Patients: A Comparative Study. Am J Trop Med Hyg. 2014.
54. Wheat LJ. Current diagnosis of histoplasmosis. Trends Microbiol. 2003;11(10):488–94.
55. Hage CA, Ribes JA, Wengenack NL, Baddour LM, Assi M, McKinsey DS, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis. 2011;53(5):448–54.
56. Wheat LJ, Musial CE, Jenny-Avital E. Diagnosis and management of central nervous system histoplasmosis. Clin Infect Dis. 2005;40(6):844–52.
57. Kauffman CA. Histoplasmosis. Clin Chest Med. 2009;30(2):217–25.
58. Connolly PA, Durkin MM, Lemonte AM, Hackett EJ, Wheat LJ. Detection of histoplasma antigen by a quantitative enzyme immunoassay. Clin Vaccine Immunol. 2007;14(12):1587–91.
59. Hage CA, Davis TE, Fuller D, Egan L, Witt 3rd JR, Wheat LJ, et al. Diagnosis of histoplasmosis by antigen detection in BAL fluid. Chest. 2010;137(3):623–8.
60. Assi M, Lakkis IE, Wheat LJ. Cross-reactivity in the Histoplasma antigen enzyme immunoassay caused by sporotrichosis. Clin Vaccine Immunol. 2011;18(10):1781–2.
61. Gutierrez ME, Canton A, Connolly P, Zarnowski R, Wheat LJ. Detection of Histoplasma capsulatum antigen in Panamanian patients with disseminated histoplasmosis and AIDS. Clin Vaccine Immunol. 2008;15(4):681–3.
62. Cloud JL, Bauman SK, Neary BP, Ludwig KG, Ashwood ER. Performance characteristics of a polyclonal enzyme immunoassay for the quantitation of Histoplasma antigen in human urine samples. Am J Clin Pathol. 2007;128(1):18–22.
63. LeMonte A, Egan L, Connolly P, Durkin M, Wheat LJ. Evaluation of the IMMY ALPHA Histoplasma antigen enzyme immunoassay for diagnosis of histoplasmosis marked by antigenuria. Clin Vaccine Immunol. 2007;14(6):802–3.
64. Cloud JL, Bauman SK, Pelfrey JM, Ashwood ER. Biased report on the IMMY ALPHA Histoplasma antigen enzyme immunoassay for diagnosis of histoplasmosis. Clin Vaccine Immunol. 2007;14(10):1389–90. author reply 90-1.
65. Theel ES, Jespersen DJ, Harring J, Mandrekar J, Binnicker MJ. Evaluation of an Enzyme Immunoassay for Detection of Histoplasma capsulatum Antigen from Urine Specimens. J Clin Microbiol. 2013.
66. Zhang X, Gibson B, Jr., Daly TM. Evaluation of commercially available reagents for the diagnosis of Histoplasmosis infection in immunocompromised patients. J Clin Microbiol. 2013.
67. Scheel CM, Samayoa B, Herrera A, Lindsley MD, Benjamin L, Reed Y, et al. Development and evaluation of an enzyme-linked immunosorbent assay to detect Histoplasma capsulatum antigenuria in immunocompromised patients. Clin Vaccine Immunol. 2009;16(6):852–8.
68. Ranque S, Pelletier R, Michel-Nguyen A, Dromer F. Platelia Aspergillus assay for diagnosis of disseminated histoplasmosis. Eur J Clin Microbiol Infect Dis. 2007;26(12):941–3.
69. Wheat LJ, Hackett E, Durkin M, Connolly P, Petraitiene R, Walsh TJ, et al. Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol. 2007;14(5):638–40.
70. Xavier MO, Pasqualotto AC, Cardoso IC, Severo LC. Cross-reactivity of Paracoccidioides brasiliensis, Histoplasma capsulatum, and Cryptococcus species in the commercial Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol. 2009;16(1):132–3.
71. Riviere S, Denis B, Bougnoux ME, Lanternier F, Lecuit M, Lortholary O. Serum Aspergillus galactomannan for the management of disseminated histoplasmosis in AIDS. Am J Trop Med Hyg. 2012;87(2):303–5.
72. Simon S, Veron V, Boukhari R, Blanchet D, Aznar C. Detection of Histoplasma capsulatum DNA in human samples by real-time polymerase chain reaction. Diagn Microbiol Infect Dis. 2010;66(3):268–73.
73. Munoz C, Gomez BL, Tobon A, Arango K, Restrepo A, Correa MM, et al. Validation and clinical application of a molecular method for identification of Histoplasma capsulatum in human specimens in Colombia, South America. Clin Vaccine Immunol. 2010;17(1):62–7.
74. Kauffman CA. Diagnosis of histoplasmosis in immunosuppressed patients. Curr Opin Infect Dis. 2008;21(4):421–5.
75. Scheel CM, Zhou Y, Theodoro RC, Abrams B, Balajee SA, Litvintseva AP. Development of a Loop-Mediated Isothermal Amplification Method for Detection of Histoplasma capsulatum DNA in Clinical Samples. J Clin Microbiol. 2013;52(2):483–8.
76. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents:recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.; 2013. p. M11-7.
77. Yeni P. Prise en charge médicale des personnes infectées par le VIH: recommandations du groupe d'expert, rapport 2010. La documentation française ed. Paris: Ministère de la Santé et des Sports; 2010.
78. Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(7):807–25.
79. Pappas PG. The role of azoles in the treatment of invasive mycoses: review of the Infectious Diseases Society of America guidelines. Curr Opin Infect Dis. 2011;24 suppl 2:S1–13.
80. Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137(2):105–9.
81. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep. 2004;53(RR-15):1–112.
82. Wheat J, Hafner R, Korzun AH, Limjoco MT, Spencer P, Larsen RA, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clin Trial Group Am J Med. 1995;98(4):336–42.
83. Hage CA, Kirsch EJ, Stump TE, Kauffman CA, Goldman M, Connolly P, et al. Histoplasma antigen clearance during treatment of histoplasmosis in patients with AIDS determined by a quantitative antigen enzyme immunoassay. Clin Vaccine Immunol. 2011;18(4):661–6.
84. Wheat J, MaWhinney S, Hafner R, McKinsey D, Chen D, Korzun A, et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Am J Med. 1997;103(3):223–32.
85. Nacher M, Adenis A, Basurko C, Vantilcke V, Blanchet D, Aznar C, et al. Primary prophylaxis of disseminated histoplasmosis in HIV patients in French Guiana: arguments for cost effectiveness. Am J Trop Med Hyg. 2013;89(6):1195–8.
86. Lenhart SW, Schafer MP, Singal M, Hajjeh RA. Histoplasmosis protecting worker at risk revised edition. In: (DHHS-NIOSH) CfDCap, editor. Atlanta: CDC; 2004. p. 39.
87. Lortholary O, Charlier C, Lebeaux D, Lecuit M, Consigny PH. Fungal infections in immunocompromised travelers. Clin Infect Dis. 2013;56(6):861–9.